Value Choices in Summary Measures of Population Health

Public Health Ethics

Volumn 10, Issue 2, 2017, Pages 176-187

  Schroeder, S Andrew ^a  

^a CLAREMONT MCKENNA COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; GLOBAL DISEASE BURDEN; HUMAN; INCIDENCE; LIFE EXPECTANCY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; RISK FACTOR; YEARS OF LIFE LOST;

EID: 85024110785     PISSN: 17549973     EISSN: 17549981     Source Type: Journal    
DOI: 10.1093/phe/phw032     Document Type: Article

References (50)

1. Anand, S. And Hanson, K. (1998). DALYs: Efficiency Versus Equity. World Development, 26, 307-310.
2. Anderson, E. (2004). Uses of Value Judgments in Science: A General Argument, with Lessons from a Case Study of Feminist Research on Divorce. Hypatia, 19, 1-24.
3. Arnesen, T. And Kapiriri, L. (2004). Can the Value Choices in DALYs Influence Global Priority-SettingHealth Policy, 70, 137-149.
4. Barker, C. And Green, A. (1996). Opening the Debate on DALYS. Health Policy and Planning, 11, 179-183.
5. Bergman, A. And 40 colleagues (2013). Science and Policy on Endocrine Disrupters must not be Mixed: A Reply to a 'Common Sense' Intervention by Toxicology Journal Editors. Environmental Health, 12, 69.
6. Betz, G. (2013). In Defense of the Value Free Ideal. European Journal for the Philosophy of Science, 3, 207-220.
7. Bognar, G. (2008). Age-Weighting. Economics and Philosophy, 24, 167-189.
8. Bray, D. (2010). The Scientific Consensus of Climate Change Revisited. Environmental Science and Policy, 13, 340-350.
9. Broome, J. (2008). Why Economics Needs Ethical Theory. In Basu, K. And Kanbur, R. (eds), Arguments for a Better World: Essays in Honor of Amartya Sen: Volume 1: Ethics, Welfare, and Measurement. Oxford: Oxford University Press, pp. 7-14.
10. Brazier, J., Ratcliffe, J., Salomon, J. A., and Tsuchiya, A. (2007). Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press.
11. Chapman, G., Hansen, K. S., Jelsma, J., Ndhlovu, C., Piotti, B., Byskov, J., and Vos, T. (2006). The Burden of Disease in Zimbabwe in 1997 as Measured by Disability-Adjusted Life Years Lost. Tropical Medicine & International Health, 11, 660-671.
12. Eyal, N., Hurst, S. A., Norheim, O. F., and Wikler, D. (eds.). (2013). Inequalities in Health: Concepts, Measures, and Ethics. Oxford: Oxford University Press.
13. Gold, M., Siegel, J., Russell, L., and Weinstein, M. (1996). Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press.
14. Haack, S. (1993). Epistemological Reflections of an Old Feminist. Reason Papers, 18, 31-43.
15. Harris, J. (1987). QALYfying the Value of Life. Journal of Medical Ethics, 13, 117-123.
16. Hausman, D. (2015). Valuing Health: Well-Being, Freedom, and Suffering. Oxford: Oxford University Press.
17. Kincaid, H., Dupré, J., and Wylie, A. (eds.). (2007). Value-Free ScienceIdeals and Illusions. Oxford: Oxford University Press.
18. Jamison, D., Shahid-Salles, S. A., Jamison, J., Lawn, J. E., and Zupan, J. (2006). Incorporating Deaths Near the Time of Birth Into Estimates of the Global Burden of Disease. In Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., and Murray, C. J. L. (eds), Global Burden of Disease and Risk Factors. Washington, DC: The World Bank, pp. 427-463.
19. Lackey, R. T. (2007). Science, Scientists, and Policy Advocacy. Conservation Biology, 21, 12-17.
20. Lyttkens, C. (2003). Time to Disable DALYsThe European Journal of Health Economics, 4, 195-202.
21. Menzel, P. (2011). Should the Value of Future Health Benefits Be Time-DiscountedIn Faust, H. And Menzel, P. (eds), Prevention vs. Treatment: What's the Right BalanceOxford: Oxford University Press.
22. Menzel, P., Dolan, P., Richardson, J., and Olsen, J. A. (2002). The Role of Adaptation to Disability and Disease in Health State Valuation: A Preliminary Normative Analysis. Social Science and Medicine, 55, 2149-2158.
23. Menzel, P., Gold, M. R., Nord, E., Pinto-Prades, J., Richardson, J., and Ubel, P. (1999). Toward a Broader View of Values in Cost-Effectiveness Analyses of Health. The Hastings Center Report, 29, 7-15.
24. Michaud, C. M. And 11 colleagues (2006). The Burden of Disease and Injury in the United States 1996. Population Health Metrics, 4, 11.
25. Murray, C. J. L. (1996). Rethinking DALYs. In Murray, C. J. L. And Lopez, A. D. (eds), The Global Burden of Disease. Geneva: World Health Organization, pp. 1-89.
26. Murray, C. And Acharya, A. (1997). Understanding DALYs. Journal of Health Economics, 16, 703-730.
27. Murray, C. J. L., Salomon, J. A., and Mathers, C. D. (2002). A Critical Examination of Summary Measures of Population Health. In Murray, C. J. L., Salomon, J. A., Mathers, C. D., and Lopez, A. D. (eds.), Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications. Geneva: World Health Organization, pp. 13-40.
28. Murray, C. J. L. And 11 colleagues (2012). Comprehensive Systematic Analysis of Global Epidemiology: Definitions, Methods, Simplification of DALYs, and Comparative Results from the Global Burden of Disease Study 2010. Lancet, 380, 1-40.
29. Murray, C. J. L. And Lopez, A. (1999). On the Comparable Quantification of Health Risks: Lessons from the Global Burden of Disease Study. Epidemiology, 10, 594-605.
30. Nord, E. (1995). The Person-Trade-Off Approach to Valuing Health Care Programs. Medical Decision Making, 15, 201-208.
31. Nord, E. (1999). Cost-Value Analysis in Health Care. Cambridge: Cambridge University Press.
32. Nord, E. (2011). Discounting Future Health Benefits: The Poverty of Consistency Arguments. Health Economics, 20, 16-26.
33. Nord, E. (2014). Cost-Value Analysis of Health Interventions: Introduction and Update on Methods and Preference Data. PharmacoEconomics, 33, 89-95.
34. Nygaard, E. (2000). Is It Feasible or Desirable to Measure Burdens of Disease as a Single NumberReproductive Health Matters, 8, 117-125.
35. Pielke, R. A. (2007). The Honest Broker. Cambridge: Cambridge University Press.
36. Plass, D., Chau, P. Y. K., Thach, T. Q. T., Jahn, H. J., Lai, P. C., Wong, C. M., and Kraemer, A. (2013). Quantifying the Burden of Disease due to Premature Mortality in Hong Kong Using Standard Expected Years of Life Lost. BMC Public Health, 13, 863.
37. Polinder, S., Haagsma, J. A., Stein, C., and Havelaar, A. H. (2012). Systematic Review of General Burden of Disease Studies Using Disability-Adjusted Life Years. Population Health Metrics, 10, 21.
38. Reidpath, D. D., Allotey, P. A., Kouame, A., and Cummins, R. A. (2003). Measuring Health in a Vacuum: Examining the Disability Weight of the DALY. Health Policy and Planning, 18, 351-356.
39. Reiss, J. (2008). Error in Economics: Towards a More Evidenced-Based Methodology. London: Routledge.
40. Robberstad, B., Hermed, Y., and Norheim, O. F. (2007). Cost-Effectiveness of Medical Interventions to Prevent Cardiovascular Disease in a Sub-Saharan African Country-the Case of Tanzania. Cost Effectiveness and Resource Allocation, 5, 3.
41. Rykiel, E. J. (2001). Scientific Objectivity, Value Systems, and Policymaking. BioScience, 51, 433-436.
42. Salomon, J. A., Mathers, C. D., Chaterji, S., Sadana, R., Üstün, T. B., and Murray, C. J. L. (2003). Quantifying Individual Levels of Health: Definitions, Concepts, and Measurement Issues. In Murray, C. J. L. And Evans, D. B. (eds), Health Systems Performance Assessment: Debates, Methods, and Empiricism. Geneva: World Health Organization, pp. 301-318.
43. Salomon, J. A. And 127 co-authors (2012). Common Values in Assessing Health Outcomes from Disease and Injury: Disability Weights Measurement Study for the Global Burden of Disease Study 2010. Lancet, 380, 2129-2143.
44. Schokkaert, E. (2015). How to Introduce more (or better) Ethical Arguments into HTAInternational Journal of Technology Assessment in Health Care, 31, 1-2.
45. Schroeder, S. A. (2012). Incidence, Prevalence, and Hybrid Approaches to Calculating Disability-Adjusted Life Years. Population Health Metrics, 10, 1-7.
46. Sunstein, C. R. And Rowell, A. (2007). On Discounting Regulatory Benefits: Risk, Money, and Intergenerational Equity. The University of Chicago Law Review, 74, 171-208.
47. Tsuchiya, A. (2000). QALYs and Ageism: Philosophical Theories and AgeWeighting. Health Economics, 9, 57-68.
48. Voigt, K. (2012). Measuring Global Health. In Lenard, P. T. And Straehle, C. (eds), Health Inequalities and Global Justice. Edinburgh: Edinburgh University Press.
49. Weinstein, M. C. And Stason, W. B. (1977). Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine, 296, 716-721.
50. Williams, A. (1997). Intergenerational Equity: An Exploration of the 'fair innings' Argument. Health Economics, 6, 117-132.